HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.

AbstractOBJECTIVE:
To investigate the potential value of serum placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), pregnancy-associated plasma protein-A (PAPP-A), free β-human chorionic gonadotropin (β-hCG) and α-fetoprotein (AFP) at 30-34 weeks' gestation in the prediction of delivery of small-for-gestational-age (SGA) neonates, in the absence of pre-eclampsia (PE).
METHODS:
This was a screening study in singleton pregnancies at 30-34 weeks' gestation, including 490 that delivered SGA neonates and 9360 cases that were unaffected by SGA, PE or gestational hypertension (normal outcome). Multivariable logistic regression analysis was used to determine if screening by serum PlGF, sFlt-1, PAPP-A, free β-hCG and AFP, individually or in combination, improved the prediction of SGA neonates provided by screening with maternal characteristics and medical history (maternal factors), and estimated fetal weight (EFW) from fetal head circumference, abdominal circumference and femur length.
RESULTS:
Compared to the normal group, the mean log10 multiples of the median (MoM) values of PlGF and AFP were significantly lower and the mean log10 MoM values of sFlt-1 and free β-hCG were significantly higher in the SGA group with a birth weight < 5(th) percentile (SGA < 5(th)) delivering < 5 weeks following assessment. The best model for prediction of SGA was provided by a combination of maternal factors, EFW and serum PlGF. Such combined screening, predicted, at a 10% false-positive rate, 85%, 93% and 92% of SGA neonates delivering < 5 weeks following assessment with birth weight < 10(th), < 5(th) and < 3(rd) percentiles, respectively; the respective detection rates of combined screening for SGA neonates delivering ≥ 5 weeks following assessment were 57%, 64% and 71%.
CONCLUSION:
Combined screening by maternal factors, EFW and serum PlGF at 30-34 weeks' gestation can identify a high proportion of pregnancies that subsequently deliver SGA neonates.
AuthorsS Bakalis, D M Gallo, O Mendez, L C Poon, K H Nicolaides
JournalUltrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (Ultrasound Obstet Gynecol) Vol. 46 Issue 2 Pg. 208-15 (Aug 2015) ISSN: 1469-0705 [Electronic] England
PMID25826797 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Chemical References
  • Biomarkers
  • Chorionic Gonadotropin, beta Subunit, Human
  • PGF protein, human
  • Pregnancy Proteins
  • alpha-Fetoproteins
  • Placenta Growth Factor
  • Vascular Endothelial Growth Factor Receptor-1
  • Pregnancy-Associated Plasma Protein-A
Topics
  • Adult
  • Biomarkers (blood)
  • Chorionic Gonadotropin, beta Subunit, Human (metabolism)
  • Female
  • Fetal Diseases (blood, diagnostic imaging)
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Small for Gestational Age (metabolism)
  • Placenta Growth Factor
  • Pre-Eclampsia (diagnosis)
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Proteins (blood)
  • Pregnancy-Associated Plasma Protein-A (metabolism)
  • Prenatal Diagnosis (methods)
  • Prospective Studies
  • Ultrasonography, Prenatal (methods)
  • Vascular Endothelial Growth Factor Receptor-1 (metabolism)
  • alpha-Fetoproteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: